Lutetium Lu 177 Vipivotide Tetraxetan Remains Effective After Sipuleucel-T in mCRPC | OncLive Lutetium Lu 177 vipivotide tetraxetan was active after treatment with sipuleucel-T in real-world mCRPC.

Real-world data show lutetium Lu 177 vipivotide tetraxetan maintains strong activity after sipuleucel-T, with median OS ~19.8 months and robust PSA responses #ProstateCancer #GUonc #mCRPC #RadioligandTherapy #Oncology
Read more ➡️ www.onclive.com/view/lutetiu...

Aggressive RCC Rising Among Younger Adults in the US - Oncology Nurse Advisor Investigators used the 2004-2021 National Cancer Database to examine contemporary RCC cases among US patients aged 20-39 years.

Although #renalCellCarcinoma is more commonly found in adults older than 60 years, recent data show a rising rate of aggressive #RCC among US adults aged 20 to 39 years. From @renalurologynews.bsky.social.

https://bit.ly/3LFcKND

#kccsm #guOnc

Minimally Invasive Inguinal Lymph Node Dissection Safer for Penile Cancer - Oncology Nurse Advisor A systematic review and meta-analysis compared the perioperative and oncologic outcomes of open versus minimally invasive inguinal lymphadenectomy during penile cancer surgery.

Minimally invasive approaches to inguinal lymph node dissection reduce morbidity without compromising oncologic outcomes in #penilecancer. Presented at #SUO25.

https://bit.ly/45OGsq4

#GUOnc

Uromigos on X: "The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer. https://t.co/h3DFbgnz3G" / X The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer. https://t.co/h3DFbgnz3G

🎶 Wondering how to tackle variant histologies in bladder cancer?

🎧 Watch here ⬇️

x.com/uromigos/sta...

@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter

Strong showing from #GUonc #patientadvocates @swog.org: Darrell Nakagawa at #S2427 BRIGHT & Joël Pointon at #CCTG-PR.26 kickoff mtgs. Exciting to see new #bladdercancer & #prostatecancer trials open! THANK YOU to SWOG GU Cmte & @supportingswog.bsky.social for including & elevating patient voices!

Top GU Immunotherapy Trials to Watch at ESMO 2025 - OncoDaily Explore 5 key immunotherapy trials in GU cancers set to shape precision oncology at ESMO 2025, from RNAseq biomarkers to ADC-IO combos.

Top GU Immunotherapy Trials to Watch at ESMO 2025

@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GUOnc #Immunotherapy #IO #ESMO25

Tian Zhang: Enjoyed the Tumor Board and Exchanging GU Oncology Insights at Peter MacCallum Cancer Centre - OncoDaily Tian Zhang: Enjoyed the Tumor Board and Exchanging GU Oncology Insights at Peter MacCallum Cancer Centre / Ben Tran, cancer, Declan Murphy, Lewis Au, Michael

Enjoyed the Tumor Board and Exchanging GU Oncology Insights at Peter MacCallum Cancer Centre - Tian Zhang
@tiansterzhangmd.bsky.social
@petermaccc.bsky.social

oncodaily.com/positive/tum...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GUOnc #PeterMac

David Planchard: The Departure of a Genito-Urinary Oncology Giant, Karim Fizazi, from Gustave Roussy - OncoDaily David Planchard: The Departure of a Genito-Urinary Oncology Giant, Karim Fizazi, from Gustave Roussy / cancer, David Planchard, genito-urinary oncology,

The Departure of a Genito-Urinary Oncology Giant, Karim Fizazi, from Gustave Roussy - David Planchard
@gustaveroussy.fr

oncodaily.com/career/genit...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GUOnc #GustaveRoussy

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care - OncoDaily Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care / cancer, Headlines, OncoDaily, oncologist near me, Oncology, Rana

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #OncologistNearMe #GUOnc

Being in Phoenix twice in 1 week is 2 times too many for me. But, #ASCO2025 awaits! 🙌 Can’t wait for another great meeting! Also, fellows & early-career #GUonc please feel free to reach out if you want to connect with a #patientadvocate! #oncsky #renalsky

Don't miss another episode of Oncology #Here and #Now a Webcast/Podcast 🎙️put out by @oncoalert.bsky.social 🚨feat my #AF colleague @barbaramelao.bsky.social on #GUonc

Busy morning @swog.org
#GUonc mtg for me & fellow #patientadvocate Darrell Nakagawa. As the #kidneycancer & #bladdercancer #patientadvocates, we’re here representing our fellow pts in #clinicaltrial development. Thanks to @supportingswog.bsky.social
& the GU cmte for empowering & including us!

SWOG 2210 is open for #prostatecancer patients w/ BRCA1 or BRCA2. Fascinating to see BRCA’s role in other cancers. Hoping we see biomarkers unlock clues in RCC soon. #GUonc #oncsky #cansky

Tian Zhang: Best practices for second line treatment in Metastatic Urothelial Carcinoma - OncoDaily Tian Zhang: Best practices for second line treatment in Metastatic Urothelial Carcinoma / Astellas, atezolizumab, Aveluma, Avelumab, Biomarker selection,

Best practices for second line treatment in Metastatic Urothelial Carcinoma - @tiansterzhangmd.bsky.social .bsky.social

oncodaily.com/url/267046

#GUOnc #UrothelialCarcinoma #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer

ICYMI: Dr. Matthew Galsky, Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses the impact of the CheckMate-901 trial results on the frontline management of mUC for #ASCODailyNews: dailynews.ascopubs.org/do/championi...
#gucsm #GUonc #GU25

A blue and orange graphic with an image of UF campus and text that reads Our GU Program is Growing! Join us! A list of requirements is included.

Our GU program is growing! We're seeking a talented medical oncologist with experience in managing patients with GU cancers and an active interest in clinical trials to join our renowned program. Learn more and apply: lnkd.in/eZZcnpdS

#GU25 #GUOnc

#Genitourinary #Oncology #GUonc #GUoncol #GUoncology #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Oncsky #Medtwitter

go.bsky.app/DtoXvaD

85 people in here now, and growing - come and join us!

#Genitourinary #Oncology #GUonc #GUoncol #GUoncology #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Oncsky #Medtwitter

go.bsky.app/DtoXvaD

66 names on this list now and growing every day - jump on!

go.bsky.app/DtoXvaD

#Genitourinary #Oncology #GUonc #GUoncology #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter

Should all men with prostate cancer get PSMA scans? Better detection but high costs - is it worth making this standard of care? 🤔 #prostatecancer #GUOnc

Bye dark ‘EX’ , hi blue sky.

#Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer

It already seems so much more pleasant here!! And love that the interface seems so familiar. Like Twitter in the good old days #urology #GUonc

Genitourinary oncology starter pack https://go.bsky.app/DtoXvaD

GU starter pack… started!
Let me know if you want to be added.
go.bsky.app/DtoXvaD

#Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter